文献速递临床试验与 GCP基础与转化研究

一项1/2期、单中心、双盲、双模拟、随机、阳性对照、年龄递减试验的研究方案:评估微针贴片递送麻腮风疫苗在健康成人(18至40岁)、麻腮风疫苗初免幼儿(15至18个月)和麻腮风疫苗未免疫婴儿中的安全性、耐受性和免疫原性

Study protocol for a phase 1/2, single-centre, double-blind, double-dummy, randomized, active-controlled, age de-escalation trial to assess the safety, tolerability and immunogenicity of a measles and rubella vaccine delivered by a microneedle patch in healthy adults (18 to 40 years), measles and rubella vaccine-primed toddlers (15 to 18 months) and measles and rubella vaccine-naïve infants (9 to
PubMed 文献 · Trials · 2022-09-14

该研究为1/2期、随机、阳性对照、双盲、双模拟、年龄递减试验,计划依次入组45名成人(18-40岁)、120名幼儿(15-18个月)和120名婴儿(9-10个月),比较麻腮风疫苗微针贴片与皮下注射麻腮风疫苗的安全性、耐受性和免疫原性。主要收集给药后14天局部和全身不良事件,第7天和第14天(仅成人队列)复查安全性实验室指标,第180天随访结束,并在基线、第42天和第180天检测麻疹和风疹血清中和抗体。

要点

  • 麻腮风疫苗微针贴片可能具有易于给药、热稳定性提高、无锐器废物、降低总体成本和无痛给药等潜在优势。
  • 这是微针贴片技术首次在儿童和婴儿中开展的临床疫苗试验。
  • 队列推进取决于独立数据监测委员会对揭盲安全性数据的审查。

核心结论

  • 该试验将提供麻腮风疫苗微针贴片使用的首批临床数据,以及微针贴片在儿科人群中使用的首批数据。
  • 该试验将指导未来产品开发决策,微针贴片技术可能是未来麻疹和风疹消除的关键技术。

研究设计与样本

  • 1/2期、随机、阳性对照、双盲、双模拟、年龄递减试验。
  • 计划依次入组45名成人(18-40岁)、120名幼儿(15-18个月)和120名婴儿(9-10个月)。
  • 参与者接受麻腮风疫苗微针贴片加0.9%氯化钠皮下注射安慰剂,或安慰剂微针贴片加皮下注射麻腮风疫苗。

主要发现

  • 给药后14天内收集局部和全身不良事件数据。
  • 第7天复查安全性实验室指标,仅成人队列在第14天复查。
  • 收集非征集性不良事件(包括严重不良事件)至每位参与者第180天最终访视。
  • 在基线、第42天和第180天检测麻疹和风疹血清中和抗体。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: New strategies to increase measles and rubella vaccine coverage, particularly in low- and middle-income countries, are needed if elimination goals are to be achieved. With this regard, measles and rubella vaccine microneedle patches (MRV-MNP), in which the vaccine is embedded in dissolving microneedles, offer several potential advantages over subcutaneous delivery. These include ease of administration, increased thermostability, an absence of sharps waste, reduced overall costs and pain-free administration. This trial will provide the first clinical trial data on MRV-MNP use and the first clinical vaccine trial of MNP technology in children and infants. METHODS: This is a phase 1/2, randomized, active-controlled, double-blind, double-dummy, age de-escalation trial. Based on the defined eligibility criteria for the trial, including screening laboratory investigations, 45 adults [18-40 years] followed by 120 toddlers [15-18 months] and 120 infants [9-10 months] will be enrolled in series. To allow double-blinding, participants will receive either the MRV-MNP and a placebo (0.9% sodium chloride) subcutaneous (SC) injection or a placebo MNP and the MRV by SC injection (MRV-SC). Local and systemic adverse event data will be collected for 14 days following study product administration. Safety laboratories will be repeated on day 7 and, in the adult cohort alone, on day 14. Unsolicited adverse events including serious adverse events will be collected until the final study visit for each participant on day 180. Measles and rubella serum neutralizing antibodies will be measured at baseline, on day 42 and on day 180. Cohort progression will be dependent on review of the unblinded safety data by an independent data monitoring committee. DISCUSSION: This trial will provide the first clinical data on the use of a MNP to deliver the MRV and the first data on the use of MNPs in a paediatric population. It will guide future product development decisions for what may be a key technology for future measles and rubella elimination. TRIAL REGISTRATION: Pan-African Clinical Trials Registry 202008836432905 . CLINICALTRIALS: gov NCT04394689.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Adigweme I, Akpalu E, Yisa M, et al. Study protocol for a phase 1/2, single-centre, double-blind, double-dummy, randomized, active-controlled, age de-escalation trial to assess the safety, tolerability and immunogenicity of a measles and rubella vaccine delivered by a microneedle patch in healthy adults (18 to 40 years), measles and rubella vaccine-primed toddlers (15 to 18 months) and measles and rubella vaccine-naïve infants (9 to 10 months) in The Gambia [Measles and Rubella Vaccine Microneedle Patch Phase 1/2 Age De-escalation Trial]. Trials. 2022. PMID: 36104719. doi:10.1186/s13063-022-06493-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。